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Summary at a glance 
Our study shows that people with bronchiectasis and chronic obstructive pulmonary disease 
(COPD) can release potentially infectious aerosols during coughing; however, no shared stains 
of Pseudomonas aeruginosa were identified in our study. The results suggest that aerosol 
transmission is an unlikely mode of cross-infection in people with bronchiectasis and COPD. 
 
Abstract 
Background and objectives: Aerosol transmission of Pseudomonas aeruginosa has been 
suggested as a possible mode of respiratory infection spread in people with cystic fibrosis (CF); 
however, whether this occurs in other suppurative lung diseases is unknown. Therefore, we 
aimed to determine if 1) people with bronchiectasis (unrelated to CF) or chronic obstructive 
pulmonary disease (COPD) can aerosolise P. aeruginosa during coughing and 2) if genetically 
indistinguishable (shared) P. aeruginosa strains are present in these disease cohorts. 
Methods: People with bronchiectasis or COPD and P. aeruginosa respiratory infection were 
recruited for two studies. Aerosol study: Participants (n=20) underwent cough testing using 
validated cough rigs to determine the survival of P. aeruginosa aerosols in the air over distance 
and duration. Genotyping Study: P. aeruginosa sputum isolates (n=95) were genotyped using 
the iPLEX20SNP platform with a subset subjected to the enterobacterial repetitive intergenic 
consensus polymerase chain reaction (ERIC-PCR) assay to ascertain their genetic relatedness. 
Results: Aerosol study: Overall, 7/20 (35%) participants released P. aeruginosa cough 
aerosols during at least one of the cough aerosol tests. These cough aerosols remained viable 
for 4-metres from source and for 15-minutes after coughing. The mean total aerosol count of 
P. aeruginosa at 2-metres was two colony forming units. Typing study: No shared  
P. aeruginosa strains were identified. 
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Conclusions: Low viable count of P. aeruginosa cough aerosols and a lack of shared  
P. aeruginosa strains observed suggesting that aerosol transmission of P. aeruginosa is an 
unlikely mode of respiratory infection spread in people with bronchiectasis and COPD. 
 
Key words (five key words in alphabetical order from MeSH list) 
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control, person-to-person transmission 
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 Infection spread in chronic lung disease 
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List of abbreviations  1 
% Percentage 
°C Celsius 
µg Microgram 
kg Kilograms 
m Metres 
mL Millilitre 
ACI Andersen cascade impactor 
BMI Body mass index 
CF Cystic fibrosis 
CFU Colony forming unit 
CI Confidence interval 
C. koseri Citrobacter koseri 
COPD Chronic obstructive pulmonary disease 
E. coli Escherichia coli 
ERIC Enterobacterial repetitive intragenic consensus 
FEV1 Forced expiratory volume in one-second 
FVC Forced vital capacity 
GNB Gram-negative bacteria 
H. influenzae Haemophilus influenzae 
HRCT High resolution computed tomography 
HREC Human Research and Ethics Committee 
IQR Inter quartile range 
MALDI-TOF Matrix-assisted laser desorption/ionisation-time-of-flight 
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P. aeruginosa Pseudomonas aeruginosa 
PCR Polymerase chain reaction 
S. maltophilia Stenotrophomonas maltophilia 
SD Standard deviation 
SNP Single nucleotide polymorphism 
spp. Species 
TPCH The Prince Charles Hospital 
  2 
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Introduction 3 
Pseudomonas aeruginosa is an opportunistic pathogen isolated from the sputum of people 4 
with underlying lung conditions. In people with cystic fibrosis (CF) over 12 years of age, P. 5 
aeruginosa is the dominant bacterial pathogen1 and cross-infection between people with CF 6 
attending specialist centres has been well-documented.2,3 The transmission route of  7 
P. aeruginosa cross-infection has been suggested as aerosol transmission with evidence that 8 
viable P. aeruginosa (and other CF pathogens) cough aerosols could travel for four metres 9 
from the source (person with CF) and remain in the air for 45-minutes after cough4,5. Yet, 10 
shared strains of P. aeruginosa have not been found in environmental sampling,6 further 11 
supporting aerosol transmission as a possible mode of cross-infection. 12 
 13 
In (non-CF) bronchiectasis and chronic obstructive pulmonary disease (COPD),  14 
P. aeruginosa predominantly causes infection in those with severe disease7,8 and is 15 
associated with poorer prognosis9, higher mortality10-12 and increased hospital admissions13. 16 
Yet unlike CF, cross-infection with P. aeruginosa is reported to be uncommon in people 17 
with bronchiectasis and COPD.14-20 Although the evidence for cross-infection is infrequent 18 
in non-CF suppurative lung diseases,15,16 the transmission mechanism of possible person-to-19 
person transmission events has not been studied previously. Therefore, we sought to 20 
determine if 1) people with bronchiectasis or COPD can produce cough aerosols containing 21 
P. aeruginosa, and 2) if respiratory infections with shared P. aeruginosa strains occurs in 22 
people with bronchiectasis and COPD attending a centre which is co-located with a large 23 
adult CF centre. 24 
 25 
Methods 26 
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Clinically stable adult participants (>18 years) who had at least one prior P. aeruginosa 27 
positive sputum culture were recruited from respiratory clinics at The Prince Charles 28 
Hospital (TPCH), Brisbane, Australia. Participants with a confirmed diagnosis of 29 
bronchiectasis had evidence of consistent radiological changes affecting ≥2 lobes by high 30 
resolution computed tomography [HRCT].21 In cases where clinical features and 31 
investigations were suggestive, CFTR mutation analysis and sweat electrolytes were 32 
performed to exclude a diagnosis of CF. The diagnosis of COPD was based on standard 33 
diagnostic criteria including symptoms and physiology. Clinical stability was defined as: no 34 
recent change in symptoms and no change in therapy including acute administration of 35 
antibiotics in the prior two weeks. Participants in the Aerosol Study were excluded if: 36 
clinically unstable and/or experienced recent haemoptysis or pneumothoraces. Written, 37 
informed consent was obtained from all participants and the studies were approved by the 38 
relevant Human Research and Ethics Committee (HREC/15/QPCH/29; 39 
HREC/11/QPCH/71). 40 
 41 
Aerosol study 42 
Cough aerosol sampling 43 
Twenty participants with bronchiectasis (n=16) or COPD (n=4) underwent cough aerosol 44 
testing using two validated cough rigs – “distance” and “duration” rigs.4,22 Participants 45 
performed up to five cough tests: two tests in the distance rig with aerosol collection points 46 
at 2- and 4-metres (order randomised), and three tests in the duration rig with aerosol ageing 47 
periods of 5-, 15- and 45-minutes. The distance and duration testing methodology have been 48 
described in detail previously with participants monitored by a healthcare professional.4,5,22 49 
In brief, participants performed respiratory function testing on the day of testing to measure 50 
forced expiratory volume in one-second (FEV1) and forced vital capacity (FVC) according 51 
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to ATS guidelines.23 Weight, height and age were recorded and the percent predicted values 52 
calculated from the Global Lung Index.24 53 
 54 
Distance testing 55 
For each cough test (2- and 4-metres), participants entered into the “distance” rig, completed 56 
2-minutes of tidal breathing to purge the lungs of room air and then proceeded to cough for 57 
5-minutes at a comfortable pace determined by each study participant. Cough aerosols were 58 
extracted continuously during this time using an Andersen Cascade Impactor (ACI) (Thermo 59 
Fisher Scientific, USA). The ACI for both distance and duration testing (see below) was 60 
loaded with Chocolate-Bacitracin media (300 µg/mL) to determine the viability of P. 61 
aeruginosa in cough aerosols.4 62 
 63 
Duration testing 64 
Participants with COPD were excluded from the duration testing due to airflow obstruction 65 
severity. For each test, the remaining bronchiectasis participants completed 2-minutes of 66 
tidal breathing to purge the lungs of room air followed by coughing for 2-minutes at a 67 
comfortable pace determined by each study participant. The cough aerosols were sealed in 68 
the rotating drum inside the duration rig, aged (5-, 15- or 45-minutes) and then extracted 69 
using an ACI as previously described.22 70 
 71 
Microbiology 72 
Qualitative and quantitative sputum cultures were performed.4,5 The aerosol agar plates were 73 
incubated aerobically at 37 °C for 72-hours. Presumptive identification of  74 
P. aeruginosa isolates was based on positive oxidase reaction and growth at 42 °C. All 75 
bacterial isolates had confirmatory identification using matrix-assisted laser 76 
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desorption/ionisation-time-of-flight (MALDI-TOF) mass spectrometry and real-time 77 
PCR.25 Sputum and aerosol P. aeruginosa colony forming units (CFU) for individual  78 
P. aeruginosa morphotypes were enumerated. The total viable count in sputum (CFU/mL) 79 
and total bacterial species aerosol count across the six-stages of the ACI were determined. 80 
Participants were defined as low (<10 total aerosol CFU) or high (≥10 total aerosol CFU 81 
count) aerosol producers.26 A hole-correction factor was applied to account for possible 82 
‘stacking’ of bacterial colonies on the agar plates inside the ACI.27 All confirmed  83 
P. aeruginosa isolates underwent genotyping using an iPLEX20SNP assay (Sequenom) for 84 
genotyping as previously published.28 85 
 86 
Genotyping Study 87 
Sputum microbiology 88 
Sputa were collected from 30 eligible participants with a recent history of P. aeruginosa 89 
infection (bronchiectasis, n=29; COPD, n=1) and cultured in an accredited clinical 90 
microbiological laboratory in accordance with local protocols (Pathology Queensland). 91 
Longitudinal sputum samples were included for analysis where available. Clinical 92 
measurements were recorded as detailed above. 93 
 94 
Genotyping 95 
Purified presumptive P. aeruginosa isolates representing different colonial morphotypes 96 
from each specimen (where possible) were selected and stored at -80 °C, with identification 97 
subsequently confirmed by real-time PCR.25 All confirmed P. aeruginosa isolates 98 
underwent iPLEX20SNP genotyping.28 The genotyping results were evaluated using a 99 
database of multilocus sequence profiles from local environmental, animal, CF and non-CF 100 
associated clinical isolates.6,28 Fourteen isolates (from nine participants) had 101 
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indistinguishable iPLEX20SNP profiles and subsequently underwent ERIC-PCR analysis29 102 
(200kb ladder was used for comparison and the gel was run at 80V for 5 hours). ERIC-PCR 103 
banding patterns were visually analysed, with isolates showing a variance of ≥1 band 104 
allocated to a different rep-PCR type. Furthermore, patterns of infection within-patients 105 
were determined.17 Clinical records were reviewed to determine possible opportunities for 106 
cross-infection such as overlapping hospital admissions, outpatient clinic appointments 107 
(including lung function appointments if available) and emergency admissions. During the 108 
study period, there were no specific infection control policies to segregate patients with 109 
bronchiectasis or COPD from each other or patients with CF when receiving inpatient care, 110 
outpatient care or during lung function testing. While the participants with bronchiectasis or 111 
COPD recruited to this study may have had contact with patients with CF, we were unable 112 
to access specific data to determine if any overlapping contact occurred (and the 113 
nature/extent of the contact. 114 
 115 
Statistical analysis 116 
Data was analysed using SPSS version 23 (IBM Corp). Categorical variables were 117 
summarised as frequency and percentage and continuous variables as mean and standard 118 
deviation. The total CFU count present in both sputum and aerosols were log transformed 119 
and reported as geometric mean and 95% confidence interval (CI). The Jeffreys 95% CI is 120 
given for the proportion of participants with P aeruginosa detected in cough aerosols. A 121 
two-tailed Pearson’s correlation was used to examine the correlation between the mean 122 
concentration of P. aeruginosa in the sputum and total mean P. aeruginosa aerosol count at 123 
2-metre testing. A linear mixed effect model with participant as the random effect and cough 124 
test as a fixed effect was used to calculate the overall mean and 95% CI for the total mean 125 
count of Gram-negative bacteria other than P. aeruginosa. Values presented in Table 1 for 126 
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the Genotyping Study are from the most recent sputum collection time point with the 127 
exception of height and weight. If the height and weight data was missing, the values 128 
recorded for the previous collection time point were used in the analysis. 129 
 130 
Results 131 
Participants 132 
The clinical characteristics of participants in the Aerosol Study (n=20) and the Genotyping 133 
Study (n=30) are summarised in Table 1. Thirteen participants were enrolled in both the 134 
aerosol and genotyping study. 135 
 136 
Aerosol study 137 
Sputum samples were obtained from 15 (75%) participants on the cough aerosol sampling 138 
testing day (Table 2) (five participants were unproductive). P. aeruginosa was cultured from 139 
12 (80%) participants who produced a sputum sample and of these participants, 7 (58%) 140 
produced cough aerosols containing P. aeruginosa. The mean concentration of  141 
P. aeruginosa in the sputum was 1.1 x 107 CFU/mL (95% CI 0.2 x 107 to 8.0 x 107) (n=12). 142 
 143 
Cough aerosol testing: P. aeruginosa 144 
All 20 participants completed the distance tests of 2- and 4-metres. Sixteen of the 145 
participants completed the 5- and 15-minute duration tests, and of these only 10 participants 146 
completed the 45-minute duration test. Seven participants (35%, 95% CI 17 - 57) produced 147 
cough aerosols containing P. aeruginosa during at least one cough tests (Table 2) and also 148 
had P. aeruginosa detected their sputum sample provided on the day of testing. P. 149 
aeruginosa positive aerosols were detected in 5/20 (25%) participants (bronchiectasis, n=4; 150 
COPD, n=1) at 2-metres, 4/20 (20%) bronchiectasis participants only at 4-metres and 2/16 151 
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(13%) bronchiectasis participants only at 15-minutes (Table 2). All participants were 152 
considered as low producers26 of P. aeruginosa cough aerosols with a total mean aerosol 153 
count of 2 CFU at 2-metres (n=5), 3 CFU at 4-metres (n=4), and 1 CFU at 15-minutes (n=2) 154 
(Table 2). No viable P. aeruginosa containing aerosols were detected in either the 5-minute 155 
test or 45-minute duration tests. The viable burden of potentially infectious aerosols released 156 
during coughing was much lower in the bronchiectasis and COPD than we have seen in CF 157 
participants.4 158 
 159 
Sputum sampling and cough aerosol testing: P. aeruginosa 160 
Genotyping of the P. aeruginosa cough aerosol isolates revealed genetically 161 
indistinguishable P. aeruginosa from paired sputum and cough aerosol isolates for the seven 162 
participants. One participant had an additional P. aeruginosa strain identified in the aerosol 163 
cultures that was not detected in the sputum sample. The total viable count of  164 
P. aeruginosa in sputum did not correlate with the total P. aeruginosa aerosol count 165 
(r=0.416, n=15, p=0.12) at 2-metres. 166 
 167 
Sputum sampling: Other Gram-negative bacteria 168 
Three (15%) participants cultured other Gram-negative bacteria (Haemophilus influenzae, 169 
Escherichia coli, Stenotrophomonas maltophilia) from the sputum (Table S1, 170 
Supplementary Information). The mean concentration of these Gram-negative bacteria in 171 
the sputum was 5.8 x 107 CFU/mL (95% CI 0.15 x 107 – 224 x 107) (other GNB sputum 172 
counts, n=4). 173 
 174 
Cough aerosol testing: Other Gram-negative bacteria 175 
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The three participants that cultured other Gram-negative bacteria from the sputum also had 176 
these bacteria recovered from ≥3 of their cough aerosols samples (H. influenzae, n=2;  177 
E. coli, n=1; S. maltophilia, n=1; Table S1, Supplementary Information); including one 178 
participant who also produced cough aerosols with P. aeruginosa (Table S1, Supplementary 179 
Information). One COPD participant did not provide a sputum sample yet produced 180 
Citrobacter koseri and Achromobacter spp. in the cough aerosol samples (Table S1, 181 
Supplementary Information). The total mean aerosol count of other Gram-negative bacteria 182 
from all distance and duration cough aerosol tests (total=19) was 22 (95% CI 2 – 181). 183 
 184 
Genotyping Study 185 
Sputum collection 186 
Sixteen (53%) of the 30 participants provided a single sputum sample. Fourteen (47%) 187 
participants provided multiple sputum samples (two, n=10 participants or three, n=4 188 
participants) and the median duration between the initial and final samples was 8.1 months 189 
(IQR 2.8 – 45.2) (Figure S1, Supplementary Information). P. aeruginosa sputum isolates 190 
were confirmed by PCR. 191 
 192 
Prevalence of shared P. aeruginosa strain infection 193 
A total of 95 confirmed P. aeruginosa sputum isolates (range: 1 to 8 isolates per participant 194 
and 1 to 4 isolates per sample) were genotyped (iPLEX20SNP) (Table S2, Supplementary 195 
Information). Of these, 3 isolates were classed as non-typeable. No dominant Australian 196 
shared CF P. aeruginosa strains (e.g. AUST-01, AUST-02 and AUST-06)6,28 were observed. 197 
In contrast, our analysis revealed 20 (67%) participants had infection with P. aeruginosa 198 
strains with genotype profiles that showed close genetic relationships to locally-derived 199 
genotypes found in the environment, animals and other non-CF clinical presentations.6 200 
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There were eight possible transmission events: one overlapping hospital admission of two 201 
participants, one overlapping emergency department attendance of two participants and six 202 
same day outpatient attendance at TPCH. None of the participants with genetically 203 
indistinguishable profiles had likely transmission events (common admissions, emergency 204 
department or outpatient attendance). The indistinguishable genotype profiles related to 205 
sequence type (ST)-17 (Clone C) (participants 1 and 9), ST-155 (participants 4 and 20), ST-206 
274 (participants 16 and 18) and ST-253 (PA14) (participants 5, 13 and 17). Representative 207 
isolates from these participants subsequently underwent ERIC-PCR and no genetically 208 
indistinguishable P. aeruginosa strains were found between the three sets of pairs or in the 209 
group of three participants.  210 
 211 
P. aeruginosa infection patterns 212 
Of the 14 participants who had multiple samples analysed, 12 (80%) harboured a single  213 
P. aeruginosa strain over time, one cultured different strains in their sputum over three time 214 
points (between 2013 and 2016) and one showed evidence of a new strain then subsequently 215 
reverting back to the original strain. 216 
 217 
Discussion 218 
Our study demonstrates that people with bronchiectasis and COPD can release aerosols 219 
containing viable P. aeruginosa during coughing; however, no shared strains of  220 
P. aeruginosa respiratory infection were detected in study participants. Our results support 221 
the published data that cross-infection of P. aeruginosa affects a minority of people with 222 
bronchiectasis14-16 and provides much needed evidence to understanding cross-infection in 223 
bronchiectasis, which was highlighted as a research priority in a recent review.30 Whilst we 224 
have demonstrated that aerosol transmission is an unlikely transmission route, it is worth 225 
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noting that the participants selected for the study were all low producers26 of  226 
P. aeruginosa cough aerosols and also, that the study participants had very few opportunities 227 
for transmission events to occur during hospital visits; thus reducing the risk of potentially 228 
being exposed to each other’s cough aerosols.  229 
 230 
The results of our cough aerosol study were in contrast to the results of previous studies in 231 
people with CF (Table 2) despite that the participant numbers were almost the same (CF 232 
cough study, n=194 versus this study, n=20). Firstly, only 25% of all participants in this 233 
study produced cough aerosols containing viable P. aeruginosa at two-metres whereas most 234 
participants with CF produced cough aerosols containing P. aeruginosa at the same 235 
distance.4 Secondly, the total mean P. aeruginosa aerosol count at 2-metres was much lower 236 
in participants with bronchiectasis or COPD compared to people with CF (2 CFU versus 39 237 
CFU, respectively) (Table 2).4 Thirdly, the distance that viable P. aeruginosa cough aerosols 238 
could travel in people with bronchiectasis, COPD or CF4 were similar (four-metres); 239 
however, the duration that P. aeruginosa cough aerosols could remain suspended in the air 240 
was shorter in people with bronchiectasis at 15-minutes compared to 45-minutes for people 241 
with CF.4 Lastly, the mean concentration of P. aeruginosa in sputum in the bronchiectasis 242 
and COPD cohort did not correlate with the total aerosol count observed at two-metres and 243 
this was in contrast to our findings in the CF cough aerosol studies.4,5,31 244 
 245 
Our genotyping study is the first Australian study to investigate the possibility of cross-246 
infection in people with bronchiectasis and COPD attending a facility which has shared 247 
inpatient and outpatient facilities with CF. Our results found that no major Australian CF 248 
shared P. aeruginosa strains33 were detected in our current cohort. In fact, our study found 249 
no evidence of shared P. aeruginosa strain infections, which is in keeping with the published 250 
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data that shared P. aeruginosa strains are uncommon in people with bronchiectasis or 251 
COPD.14-17,19,20 The P. aeruginosa strains detected in our study are commonly found in other 252 
niches such as the natural environment and non-CF infections.3,6,14,34 Our longitudinal 253 
analysis of P. aeruginosa isolates showed that the majority of participants retained the same 254 
unique P. aeruginosa strain over time which is consistent with other recent 255 
studies.15,17,19,20,35 These results suggest that person-to-person transmission of P. aeruginosa 256 
is unlikely to occur in people with bronchiectasis and COPD. Instead, P. aeruginosa 257 
respiratory infection is likely acquired from the natural environment. 258 
 259 
Interestingly, our study found four of the 20 participants produced cough aerosols containing 260 
other Gram-negative bacteria. This was a higher proportion than in our previous CF P. 261 
aeruginosa cough aerosol studies4,31,32 which is likely to be related to the difference in 262 
infection profile in people with bronchiectasis and COPD compared with CF populations. 263 
Incidentally, we found two study participants with bronchiectasis who were high producers 264 
of H. influenzae cough aerosols,26 a common respiratory pathogen of people with 265 
bronchiectasis and COPD.36-40 Whilst H. influenzae cross-infection is not thought to occur 266 
in people with bronchiectasis,18 it has been recently reported in a single study of people with 267 
CF;41 though it is presently unclear if aerosol transmission plays a role in H. influenzae 268 
acquisition. Our study reported one non-expectorating participant with COPD who produced 269 
cough aerosols containing C. koseri and Achromobacter spp. The finding of potentially 270 
infectious cough aerosols in the absence of sputum production was also reported in our 271 
earlier cough studies in people with CF4,42 yet was in contrast to our two most recent studies 272 
in people with CF which found that people with CF who could not expectorate sputum were 273 
unable to generate potentially infectious cough aerosols.31,32 274 
 275 
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This study had several limitations. Firstly, most people with COPD and P. aeruginosa 276 
respiratory infection were unsuitable for participation because they had severe airflow 277 
obstruction which impacts on the generalisability of our results in these patients. Therefore, 278 
a larger study using altered study protocols may better include participants with COPD and 279 
may support stronger correlations between clinical and microbiological measures and 280 
aerosol CFU counts. Secondly, our sample size was small and the number of participants 281 
which produced viable P. aeruginosa in their cough aerosols was low. Therefore robust 282 
estimates cannot be determined however, the estimates obtained in this study are useful for 283 
calculation of sample size for future cough aerosol studies. Similarly, given that the number 284 
of participants in the Genotype Study had a median follow-up time of less than 12 months, 285 
the diversity of genetic variation of P. aeruginosa in patients with bronchiectasis may have 286 
also been underestimated. Thirdly, the infectious dose of  287 
P. aeruginosa and other Gram-negative bacteria is not known and therefore, the risk of 288 
infection from exposure to potentially infectious aerosols remains uncertain. Fourthly, the 289 
study participants were tested when clinically stable and therefore, may underestimate the 290 
P. aeruginosa aerosols released during pulmonary exacerbations. Fifthly, the media used to 291 
capture the cough aerosols was selective for Gram-negative bacteria and thus, the results of 292 
this study cannot be generalised to those people with bronchiectasis and COPD harbouring 293 
Gram-positive bacterial respiratory infections. Finally, the longitudinal analyses, at times, 294 
included one isolate per sputum which limited the capacity to detect strain diversity. 295 
 296 
Our study has demonstrated that people with bronchiectasis and COPD can release low 297 
amounts of viable P. aeruginosa aerosols during coughing. The result confirms the finding 298 
that P. aeruginosa cross-infection is uncommon in bronchiectasis and that aerosol 299 
transmission seems unlikely to be a major contributor to P. aeruginosa cross-infection. 300 
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Table 1: Demographics and clinical characteristics of study participants 
Patient Characteristics Aerosol study Typing study* (n=20) (n=30) 
Age (years), mean (SD) 62.5 (11.0) 64.0 (8.8) 
Sex, male, n (%) 6 (30%) 10 (33%) 
FEV1 % predicted, mean (SD) 56.7 (20.7) 58.7 (18.1) 
FVC % predicted, mean (SD) 76.5 (16.6) 75.0 (17.0) 
BMI (kg/m2), mean (SD) 25.3 (4.3) 26.7 (5.6)^ 
Ethnicity   
Caucasian 19 (95%) 29 (97%) 
Asian 1 (5%) 1 (3%) 
Clinical disease   
Bronchiectasis, n (%) 16 (80%) 29 (97%) 
Idiopathic, n (%) 1 (6%) 10 (34%) 
Childhood infection, n (%) 14 (88%) 15 (52%) 
Pink’s Disease, n (%) 1 (6%) 2 (7%) 
Kartageners Syndrome, n (%) 0 (0%) 1 (3%) 
Aspiration, n (%) 0 (0%) 1 (3%) 
COPD, n (%) 4 (20%) 1 (3%) 
Subjects that contributed multiple sputum samples, n (%) n/a 14 (47%) 
Time under observation (months), median (IQR) n/a 8.1 (2.8 – 45.2) 
Chronic P. aeruginosa infection, n (%) 17 (85%) 25 (83%) 
Smoking history   
Bronchiectasis cohort:   
Never, n (%) 14/16 (88%) 22/29 (76%) 
Former, n (%) 2/16 (13%) 7/29 (24%) 
- Pack years, median (IQR) (1, 2)~ 8 (2 – 20) 
COPD cohort:   
Never, n (%) 2#/4 (50%) 1/1 (100%) 
Former, n (%) 2/4 (50) n/a 
- Pack years, median (IQR) (45, 85)~ n/a 
*n=13 also participated in the Aerosol Study; ^n=28; ~individual pack years; #One COPD 
participant had alpha-1 antitrypsin deficiency and the other COPD participant had 
longstanding asthma); n/a, not applicable. 
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Table 2: Comparison of P. aeruginosa in sputum and in cough aerosols 
 Participants 
n = 20 
Previously published CF cough study4* 
n = 19~ 
Sputum n (%) CFU/mL, geometric mean (95% CI) n (%) CFU/mL, geometric mean (SD) 
Sputum provided 
- All participants 
o Bronchiectasis 
o COPD 
 
15 (75) 
14/16 (88) 
1/4 (25) 
 18 (95)  
P. aeruginosa detected in sputum 
- All participants 
o Bronchiectasis 
o COPD 
 
12^/15 (80) 
11/14 (79) 
1/1 (100) 
 
1.1 x 107 (0.2 x 107 – 8.0 x 107) 
 
 
 
18/18 (100) 
 
 
 
13.7 x 107 (2.2 x 107– 106.0 x 107) 
 
 
Cough aerosol  Count (CFU), geometric mean (95% CI)  Count (CFU), geometric mean (95% CI) 
P. aeruginosa detected in cough aerosol 
o All participants 
o Bronchiectasis 
o - COPD 
 
7/20 (35) 
6/16 (38) 
1/4 (25) 
 
- 
- 
- 
18/18 (100) 
- 
- 
 
- 
- 
- 
Distance 
- 2-metres 
- 4-metres 
 
5^/20 (25) 
4^/20 (20) 
 
2 (1 - 7) 
3 (1 - 9) 
 
17/18 (94) 
17/18 (94) 
 
39 (30 – 51) 
26 (20 – 34) 
Duration 
- 5-minutes 
- 15-minutes 
 45-minutes 
 
0/16 (0) 
2^/16 (13) 
0/10 (0) 
 
0 
1 (-1 – 31) 
0 
 
15/18 (83) 
14/18 (78) 
14/18 (78) 
 
15 (11 – 20) 
12 (9 – 16) 
8 (6 – 11) 
CF, cystic fibrosis; CFU, colony forming unit; mL, millilitre; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ~includes cough 
swab from one participant;^numerator represents the number of participants included in the geometric mean calculations; *data taken from Knibbs et al4 
online supplement, table S3. 
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